as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹1,003.35
Change
-20.7 (-2.02%)
Open
₹1,023.0
Prev. Close
₹1,024.05
Day High
₹1,027.85
Day Low
₹985.5
Volume Analysis
Traded
675,920
Delivered
308,676
Delivery %
45.67%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (27.0%)
Weaknesses (0)
No signal for this stock
Opportunities (1)
- •Strong 3-year revenue growth (15.3%)
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,067.99 | ₹1,047.92 | ₹1,025.64 | ₹1,005.57 | ₹983.29 | ₹963.22 | ₹940.94 |
| Fibonacci | ₹1,047.92 | ₹1,031.74 | ₹1,021.75 | ₹1,005.57 | ₹989.39 | ₹979.4 | ₹963.22 |
| Camarilla | ₹1,015.0 | ₹1,011.11 | ₹1,007.23 | ₹1,005.57 | ₹999.47 | ₹995.59 | ₹991.7 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
—
1 Week
-13.21%
1 Month
—
3 Months
—
6 Months
—
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
DuPont ROE Breakdown
9.62%
Net margin 12.66% × asset turnover 0.49x × equity multiplier 1.55x
Company Overview
Sector
Healthcare
Market Cap
₹6,447 Cr
P/E (TTM)
64.8
ROE
11.7%
Face Value
₹2.0
Source: Screener.in (Consolidated figures) — data as of 27 Sep 2026. Not investment advice.
TopFund Analysis
Symbiotec Pharmalab Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 52/100. The strongest factor is Financial Strength (98/100), while Valuation (0/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (27.0%). Strong 3-year revenue growth (15.3%).
TopFund Score — Fundamentals Quality
52/100 — AverageData confidence: 73/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Liquidity
From Screener.in
- +Company has reduced debt.
- −Promoter holding is low: 33.3%
- −Company has a low return on equity of 12.9% over last 3 years.
- −Company might be capitalizing the interest cost
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Audio recording link for Q1 FY2027 earnings conference call held September 22, 2026.
Pursuant to regulation 30 and 47 of SEBI Listing Regulations, the copies of newspaper publication is attached herewith.
Q1FY27 revenue rose to Rs 218.2 crore; PAT was Rs 14.1 crore; first DCV ANDA filed.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|
| Sales + | 203 | 245 | 218 |
| Expenses + | 145 | 183 | 173 |
| Operating Profit | 58 | 62 | 45 |
| OPM % | 29.0% | 25.0% | 21.0% |
| Other Income + | 3 | 0 | 0 |
| Interest | 5 | 7 | 6 |
| Depreciation | 11 | 20 | 22 |
| Profit before tax | 45 | 35 | 18 |
| Tax % | 33.0% | 22.0% | 20.0% |
| Net Profit + | 30 | 28 | 14 |
| EPS in Rs | 47 | 4 | 2 |
| Raw PDF | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales + | 633 | 682 | 567 | 716 | 752 | 869 |
| Expenses + | 438 | 550 | 497 | 544 | 549 | 630 |
| Operating Profit | 195 | 131 | 70 | 172 | 203 | 239 |
| OPM % | 31.0% | 19.0% | 12.0% | 24.0% | 27.0% | 27.0% |
| Other Income + | 7 | 3 | 6 | 7 | 4 | -6 |
| Interest | 7 | 3 | 8 | 8 | 17 | 26 |
| Depreciation | 22 | 26 | 29 | 39 | 43 | 53 |
| Profit before tax | 173 | 105 | 39 | 132 | 147 | 153 |
| Tax % | 28.0% | 27.0% | 38.0% | 23.0% | 34.0% | 28.0% |
| Net Profit + | 123 | 78 | 23 | 100 | 97 | 110 |
| EPS in Rs | 113 | 71 | 21 | 91 | 152 | 18 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Reserves | 510 | 588 | 611 | 704 | 804 | 1,137 |
| Borrowings + | 47 | 65 | 218 | 247 | 544 | 391 |
| Other Liabilities + | 200 | 152 | 151 | 326 | 220 | 240 |
| Total Liabilities | 768 | 815 | 990 | 1,289 | 1,580 | 1,781 |
| Fixed Assets + | 261 | 280 | 299 | 448 | 438 | 1,120 |
| CWIP | 28 | 40 | 182 | 208 | 568 | 64 |
| Investments | 5 | 5 | 5 | 4 | 1 | 4 |
| Other Assets + | 474 | 490 | 504 | 628 | 572 | 592 |
| Total Assets | 768 | 815 | 990 | 1,289 | 1,580 | 1,781 |
| Equity Capital | 11 | 11 | 11 | 11 | 11 | 13 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 174 | 18 | 69 | 188 | 47 | 175 |
| Cash from Investing Activity + | -96 | -32 | -220 | -206 | -307 | -227 |
| Cash from Financing Activity + | -79 | 15 | 146 | 22 | 278 | 36 |
| Net Cash Flow | -1 | 1 | -5 | 3 | 19 | -16 |
| CFO/OP | 112 | 36 | 124 | 129 | 40 | 99 |
| Free Cash Flow | 87 | -55 | -155 | -22 | -261 | -50 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2026 | |
|---|---|
| Public | 18.12% |
| Promoters | 33.28% |
| FII | 21.08% |
| DII | 27.51% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Symbiotec Pharmalab Ltd (this stock) | 6,447 | 64.8 | — | 11.7% |
| Orchid Pharma Limited | 6,377 | 353.0 | 3.55 | 1.49% |
| Morepen Lab. Ltd | 6,596 | 56.2 | 5.26 | 5.33% |
| Kovai Medical Center & Ho | 6,653 | 115.0 | 23.07 | 22.2% |
| Senores Pharmaceuticals L | 6,241 | 49.4 | 6.67 | 13.4% |
| Sun Pharma Adv.res.co.ltd | 6,784 | 4.25 | 5.06 | 279.0% |
| Iol Chem And Pharma Ltd | 5,965 | 33.8 | 3.31 | 8.41% |
Which Mutual Funds Hold Symbiotec Pharmalab Ltd?
Frequently Asked Questions about Symbiotec Pharmalab Ltd
Symbiotec Pharmalab Ltd (SYMBIOTEC) closed at ₹1,003.35 on NSE on 25 September 2026, down 20.7 (2.02%) from the previous close.
Symbiotec Pharmalab Ltd trades on the NSE (National Stock Exchange of India) under the symbol SYMBIOTEC.
Symbiotec Pharmalab Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 64.8.
Symbiotec Pharmalab Ltd has a dividend yield of 0.0%.
Symbiotec Pharmalab Ltd's 52-week high is ₹1,194.0 and its 52-week low is ₹934.0.
Symbiotec Pharmalab Ltd has a market capitalisation of ₹6,447 crore.
Symbiotec Pharmalab Ltd has a TopFund Quality Score of 52/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Symbiotec Pharmalab Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.